Salt Drives Gut-Brain Connection via IL-17

Save

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

The RheumNow Week in Review - 8 December 2017

Save

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis

Save

The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

The RheumNow Week in Review - 17 November 2017

Save

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk

Save

JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents.  (Citation source 

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

Save

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when

Gut-derived TNF: Connection Between Crohn’s and SpA and Sacroiliitis

Save

The pathogenesis between microscopic gut inflammation leading to the development of Crohn’s disease and sacroiliitis has been poorly understood. Dr. Debusschere, et al sought to understand this important link between IBD and axial SpA.

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Save

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein.

Biosimilars Projected to Yield $54 Billion in Savings

Save

A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers. 

Stelara FDA Approved for Use in Adolescent Psoriasis

Save

Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.

IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases

Save

A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).

Safety of Long-Term PPI Use

Save

The current issue of JAMA reviews the safety of long-term use of proton pump inhibitors (PPI). The following is a collection of the evidence about these purported risks.

Fractures

15 September 2017 The RheumNow Week in Review

Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

New Recommendations on Biosimilar Use

Save

The introduction of a growing number of biosimilars into the market poses a substantial change in cost of care for patients with inflammatory rheumatologic disorders.  

Adalimumab Biosimilars Adding Up

Save

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

Kids with Crohn's have Profound MSK Deficits - but No Increase in Fractures

Save

Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract, is also known for its propensity to affect the musculoskeletal system.

Pediatric Consensus on Comorbidity Assessments

Save

Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.

NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications

Save

Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.

NSAIDs Increase Risk of Acute Myocardial Infarction

Save

Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.

Increased Comorbidities in Rheumatoid Arthritis

Save

A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.